ARTICLE | Company News
FDA snubs Brinavess resubmission for AF
August 21, 2017 9:17 PM UTC
Cardiome Pharma Corp. (TSX:COM; NASDAQ:CRME) said FDA informed the company that its proposed data package for IV Brinavess vernakalant to treat atrial fibrillation would not be sufficient to support resubmission of an NDA.
On Monday, Cardiome lost C$1.73 (35%) to C$3.26 in Toronto and fell $1.27 (33%) to $2.60 on NASDAQ...
BCIQ Company Profiles